IP Library Granted Patent US 11,337,930
Granted Patent B2
US 11,337,930 · App. 17/080,355 · Granted May 24, 2022

Modified alginates for cell encapsulation and cell therapy

Inventors: Arturo J. Vegas (Belmont, MA); Minglin Ma (Ithaca, NY); Kaitlin M. Bratlie (Ames, IA); Daniel G. Anderson (Framingham, MA); Robert S. Langer (Newton, MA)
Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE CHILDREN'S MEDICAL CENTER CORPORATION
A61K9/5036A61K9/0024A61K35/39A61K45/06C08B37/0084A61K9/5161
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,337,930
App. No.
17/080,355
Granted
May 24, 2022
Kind
B2
Abstract

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

Claims (7)

1. A method of treating a disease or disorder in a human or animal patient, comprising:

implanting or transplanting into a human or animal patient a biological material encapsulated in an ionically crosslinked biocompatible multiply modified alginate which is

2. The method of claim 1 , wherein the biological material is cells.

3. The method of claim 2 , wherein the disease or disorder is diabetes and the cells are pancreatic islet cells.

4. The method of claim 1 , wherein the modified alginate is further crosslinked covalently.

5. The method of claim 1 , wherein the modified alginate is in a matrix that further comprises unmodified alginate.

6. The method of claim 1 , wherein the biological materials is encapsulated in a microcapsule comprising the modified alginate.

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 12, 2022
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061656/0945 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2020
From: VEGAS, ARTURO J.; MA, MINGLIN; BRATLIE, KAITLIN M.; ANDERSON, DANIEL G.; LANGER, ROBERT S.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 054272/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2020
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY; THE CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 054272/0330 →
Continuity (6)
Division 16408899 · May 10, 2019
Continuation 15588481 · May 5, 2017
Continuation 15208192 · Jul 12, 2016
Continuation 13487524 · Jun 4, 2012
Provisional Application 61492705 · Jun 2, 2011
Related Publication 20210186886A1 · Jun 24, 2021
Cited By (1)
US 12,306,081